Sort   by:  
 Page size 
We show the molecular and functional characterization of a novel population of lineage-negative CD34-negative (Lin- CD34-) hematopoietic stem cells (HSCs) from chronic myelogenous leukemia (CML) patients at diagnosis. Molecular caryotyping and quantitative analysis of BCR/ABL transcript demonstrated...
ORGANISM(S): Homo sapiens 
ABL1 kinase inhibitors such as imatinib mesylate (IM) are effective in managing chronic myelogenous leukemia (CML) but incapable of eliminating leukemia stem cells (LSCs), suggesting that kinaseM-bM-^HM-^Rindependent pathways support LSC survival. Given that the bone marrow hypoxic microenvironment ...
ORGANISM(S): Homo sapiens 
Not available
ORGANISM(S): Mus musculus 
Imatinib therapy is first-line treatment for chronic myeloid leukemia (CML), and its failure to target CML progenitor/stem cells may lead to an increased risk of relapse. We report here that fenretinide, a well-tolerated vitamin A derivative, is capable of eradicating primitive CML progenitor/stem c...
ORGANISM(S): Homo sapiens 
Quiescent and dividing hemopoietic stem cells (HSC) display marked differences in their ability to move between the peripheral circulation and the bone marrow. Specifically, long-term engraftment potential predominantly resides in the quiescent HSC subfraction, and G-CSF mobilization results in the ...
ORGANISM(S): Homo sapiens 
Background MicroRNAs are important regulators of transcription in hematopoiesis. Their expression deregulations were described in association with pathogenesis of some hematological malignancies. This study provides integrated microRNA expression profiling at different phases of chronic myeloid leu...
ORGANISM(S): Homo sapiens 
Profiling CD34+ BCR-ABL+ cells of CML patients in chronic phase or blast crisis to identify differentially expressed stage-specific genes.
ORGANISM(S): Homo sapiens 
The outcome of treating chronic myeloid leukemia (CML) with imatinib mesylate (IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared to early chronic phase. This may be attributed to additional genomic alterations that accumulate during disease progression. We so...
ORGANISM(S): Homo sapiens 
Comparison of gene expression profiles of CD34+ hematopoietic stem and progenitor cells from bone marrow of patients with untreated chronic myelogenous leukemia (CML) in chronic phase with those from bone marrow of healthy volunteers. Chronic myelogenous leukaemia (CML) is a malignant disorder of th...
ORGANISM(S): Homo sapiens 
We investigated the ability of HDAC inhibitors (HDACi) to target CML stem cells. Treatment with HDACi combined with IM effectively induced apoptosis in quiescent CML progenitors resistant to elimination by IM alone, and eliminated CML stem cells capable of engrafting immunodeficient mice. In vivo ad...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size